Design of Small Molecules with HIV Fusion Inhibitory Property Based on Gp41 Interaction Assay

Overview

Journal Avicenna J Med Biotechnol

Specialty Biomedical Engineering

Date 2013 Jun 27

PMID 23799176

Authors

Soroush Sardari

Kayhan Azadmanesh

Fereidoun Mahboudi

Asghar Davood

Ruhollah Vahabpour

Rezvan Zabihollahi

Hosna Gomari

Affiliations

Soon will be listed here.

Abstract

Background: Gp41 of HIV (Human Immunodeficiency Virus) is a protein that mediates fusion between viral and cellular membranes. The agent, T-20, which has been approved for HIV inhibition, can restrain Gp41 function in the fusion process; nevertheless, it has disadvantages like instability, high cost of production and injection form to be delivered twice a day.

Methods: Several molecules like NB-2 and NB-64 have been discovered that can inhibit HIV infection. These molecules were used as template compounds to design and develop more effective small molecules functioning as HIV-1 fusion inhibitors targeting Gp41. The process included in silico docking protocols using HEX and ArgusLab applications. A multisource database was created, after choosing the best molecules; they were tested in vitro for inhibitory activity by HIV-1 single-cycle model, transfected in HEK cells (293T).

Results: Computational analysis and experimental data were combined to explore molecular properties and the most potent ones were found, with the best suitable criteria for interaction with Gp41. Several examples (DAA-6, DAA-9 and DAA-12) could inhibit infection in vitro as effective as NB-2, NB-64.

Conclusion: Since disadvantages of available fusion inhibitor (T-20), it seems necessary to find similar molecules to be approved and have small size providing suitable bioactivity profile. The molecules explored in this study can be good candidates for further investigations to be used as oral HIV fusion inhibitors in the future.

References

Yao X, Chong H, Zhang C, Waltersperger S, Wang M, Cui S . Broad antiviral activity and crystal structure of HIV-1 fusion inhibitor sifuvirtide. J Biol Chem. 2012; 287(9):6788-96. PMC: 3307288. DOI: 10.1074/jbc.M111.317883. View

Tan J, Kong R, Wang C, Chen W . Prediction of the binding model of HIV-1 gp41 with small molecule inhibitors. Conf Proc IEEE Eng Med Biol Soc. 2007; 2005:4755-8. DOI: 10.1109/IEMBS.2005.1615534. View

Lee-Huang S, Huang P, Zhang D, Lee J, Bao J, Sun Y . Discovery of small-molecule HIV-1 fusion and integrase inhibitors oleuropein and hydroxytyrosol: Part I. fusion [corrected] inhibition. Biochem Biophys Res Commun. 2007; 354(4):872-8. PMC: 2790717. DOI: 10.1016/j.bbrc.2007.01.071. View

Debnath A, RADIGAN L, Jiang S . Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1. J Med Chem. 1999; 42(17):3203-9. DOI: 10.1021/jm990154t. View

Zhao Q, Ernst J, Hamilton A, Debnath A, Jiang S . XTT formazan widely used to detect cell viability inhibits HIV type 1 infection in vitro by targeting gp41. AIDS Res Hum Retroviruses. 2002; 18(14):989-97. DOI: 10.1089/08892220260235353. View

Rutenber E, Fauman E, Keenan R, Fong S, Furth P, Ortiz de Montellano P . Structure of a non-peptide inhibitor complexed with HIV-1 protease. Developing a cycle of structure-based drug design. J Biol Chem. 1993; 268(21):15343-6. View

Frey G, Rits-Volloch S, Zhang X, Schooley R, Chen B, Harrison S . Small molecules that bind the inner core of gp41 and inhibit HIV envelope-mediated fusion. Proc Natl Acad Sci U S A. 2006; 103(38):13938-43. PMC: 1599892. DOI: 10.1073/pnas.0601036103. View

Furuta R, Nishikawa M, Fujisawa J . Real-time analysis of human immunodeficiency virus type 1 Env-mediated membrane fusion by fluorescence resonance energy transfer. Microbes Infect. 2005; 8(2):520-32. DOI: 10.1016/j.micinf.2005.08.004. View

Jiang S, Zhao Q, Debnath A . Peptide and non-peptide HIV fusion inhibitors. Curr Pharm Des. 2002; 8(8):563-80. DOI: 10.2174/1381612024607180. View

10.

Liu S, Wu S, Jiang S . HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds. Curr Pharm Des. 2007; 13(2):143-62. DOI: 10.2174/138161207779313722. View

11.

Teissier E, Penin F, Pecheur E . Targeting cell entry of enveloped viruses as an antiviral strategy. Molecules. 2011; 16(1):221-50. PMC: 6259279. DOI: 10.3390/molecules16010221. View

12.

Zabihollahi R, Sadat S, Vahabpour R, Aghasadeghi M, Memarnejadian A, Ghazanfari T . Development of single-cycle replicable human immunodeficiency virus 1 mutants. Acta Virol. 2011; 55(1):15-22. DOI: 10.4149/av_2011_01_15. View

13.

Hanna G, Lalezari J, Hellinger J, Wohl D, Nettles R, Persson A . Antiviral activity, pharmacokinetics, and safety of BMS-488043, a novel oral small-molecule HIV-1 attachment inhibitor, in HIV-1-infected subjects. Antimicrob Agents Chemother. 2010; 55(2):722-8. PMC: 3028796. DOI: 10.1128/AAC.00759-10. View

14.

Jiang S, Lu H, Liu S, Zhao Q, He Y, Debnath A . N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion. Antimicrob Agents Chemother. 2004; 48(11):4349-59. PMC: 525433. DOI: 10.1128/AAC.48.11.4349-4359.2004. View

15.

Seki J, Ikeda R, Hoshino H . Dimethyl sulfoxide and related polar compounds enhance infection of human T cells with HIV-1 in vitro. Biochem Biophys Res Commun. 1996; 227(3):724-9. DOI: 10.1006/bbrc.1996.1576. View

16.

Najmanovich R, Allali-Hassani A, Morris R, Dombrovsky L, Pan P, Vedadi M . Analysis of binding site similarity, small-molecule similarity and experimental binding profiles in the human cytosolic sulfotransferase family. Bioinformatics. 2007; 23(2):e104-9. DOI: 10.1093/bioinformatics/btl292. View

17.

Teixeira C, Barbault F, Rebehmed J, Liu K, Xie L, Lu H . Molecular modeling studies of N-substituted pyrrole derivatives--potential HIV-1 gp41 inhibitors. Bioorg Med Chem. 2008; 16(6):3039-48. DOI: 10.1016/j.bmc.2007.12.034. View

18.

Melikyan G, Platt E, Kabat D . The role of the N-terminal segment of CCR5 in HIV-1 Env-mediated membrane fusion and the mechanism of virus adaptation to CCR5 lacking this segment. Retrovirology. 2007; 4:55. PMC: 1995219. DOI: 10.1186/1742-4690-4-55. View

19.

Si Z, Madani N, Cox J, Chruma J, Klein J, Schon A . Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins. Proc Natl Acad Sci U S A. 2004; 101(14):5036-41. PMC: 387369. DOI: 10.1073/pnas.0307953101. View

20.

Blanco J, Clotet-Codina I, Bosch B, Armand-Ugon M, Clotet B, Este J . Multiparametric assay to screen and dissect the mode of action of anti-human immunodeficiency virus envelope drugs. Antimicrob Agents Chemother. 2005; 49(9):3926-9. PMC: 1195414. DOI: 10.1128/AAC.49.9.3926-3929.2005. View